MedPath

Medexus Pharma, Inc.

Medexus Pharma, Inc. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2012-01-01
Employees
51
Market Cap
-
Website
http://www.medacpharma.com

Clinical Trials

3

Active:0
Completed:2

Trial Phases

2 Phases

Phase 2:1
Phase 3:2

Drug Approvals

4

FDA:4

Drug Approvals

Ixinity

Approval Date
Apr 3, 2024
FDA

GLEOLAN

Approval Date
Jan 10, 2024
FDA

Rasuvo

Approval Date
Sep 1, 2023
FDA

Hexatrione

Approval Date
Jan 10, 2023
FDA

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 3
2 (66.7%)
Phase 2
1 (33.3%)

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

Phase 3
Completed
Conditions
Hemophilia B
Interventions
First Posted Date
2019-02-26
Last Posted Date
2024-05-16
Lead Sponsor
Medexus Pharma, Inc.
Target Recruit Count
21
Registration Number
NCT03855280
Locations
🇧🇷

Centro Estadual de Hemopterapia e Hematologia do Espirito Santo, Vitória, Espirito Santo, Brazil

🇧🇷

Universidade Estadual de Campinas - Centro de Hematologia e Hemoterapia, Campinas, Brazil

🇧🇷

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, Brazil

and more 8 locations

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Phase 3
Terminated
Conditions
Hemophilia B
First Posted Date
2011-01-07
Last Posted Date
2021-03-15
Lead Sponsor
Medexus Pharma, Inc.
Target Recruit Count
9
Registration Number
NCT01271868
Locations
🇺🇸

RUSH University Medical Center, Chicago, Illinois, United States

🇺🇸

Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, United States

🇺🇸

Gulf States Hemophilia & Thrombophilia Center, Houston, Texas, United States

and more 7 locations

Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

Phase 2
Completed
Conditions
Hemophilia B
First Posted Date
2008-10-08
Last Posted Date
2021-04-06
Lead Sponsor
Medexus Pharma, Inc.
Target Recruit Count
77
Registration Number
NCT00768287
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

The Hemophilia Treatment Center of Orthopaedic Hospital, Los Angeles, California, United States

🇺🇸

Emory University School of Medicine Pediatric Hematology, Atlanta, Georgia, United States

and more 20 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.